In re Skelaxin (Metaxalone) Antitrust Litigation, No. 12-MD-2343 (E.D. Tenn.)

In this case, nicknamed Skelaxin, Faruqi & Faruqi, LLP represented a pharmaceutical wholesaler and a class of direct purchasers of the muscle relaxant drug Skelaxin (metaxalone), which has been on the market, without generic competition, since the 1960s. The suit alleged that the brand manufacturer (King) and a generic drug company (Mutual), conspired to delay generic competition until 2010, in violation of §§ 1 and 2 of the Sherman Act. As a result of the alleged scheme, the suit alleged, class members incurred overcharge damages in the hundreds of millions of dollars. A settlement of $73 million was reached in late 2013 with Defendants and was finally approved by the court on September 24, 2014.